BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Exley MA, Garcia S, Zellander A, Zilberberg J, Andrews DW. Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma. J Clin Med 2022;11:1069. [PMID: 35207340 DOI: 10.3390/jcm11041069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tatari N, Khan S, Livingstone J, Zhai K, Mckenna D, Ignatchenko V, Chokshi C, Gwynne WD, Singh M, Revill S, Mikolajewicz N, Zhu C, Chan J, Hawkins C, Lu JQ, Provias JP, Ask K, Morrissy S, Brown S, Weiss T, Weller M, Han H, Greenspoon JN, Moffat J, Venugopal C, Boutros PC, Singh SK, Kislinger T. The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers. Acta Neuropathol 2022;144:1127-42. [PMID: 36178522 DOI: 10.1007/s00401-022-02506-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Giotta Lucifero A, Luzzi S. Emerging immune-based technologies for high-grade gliomas. Expert Rev Anticancer Ther 2022. [PMID: 35924820 DOI: 10.1080/14737140.2022.2110072] [Reference Citation Analysis]